anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Verbal WM tasks - particularly letter span and digit span tasks - and a visuospatial WM task are most commonly used (e.g. Dahlin et al., 2008; Klingberg et al., 2005; Westerberg et al., 2007). Therefore, a multiple-task training including these tasks will be administered to the third group.
1. A pharmaceutical composition, comprising: a). i) paracetamol, ii) 1 to 4 parts by volume of ethanol for each part by weight of paracetamol, and iii) 1 to 5 parts by volume of a polyethylene glycol for each part by weight of paracetamol, b).wherein said composition is substantially anhydrous, and c). said composition forms a clear solution for injection with the addition of 4-10 parts by volume of water for each part by weight of paracetamol. 2. A clear pharmaceutical composition for injection, comprising paracetamol and, for each part by weight of paracetamol, i) 1 to 4 parts by volume of ethanol, ii) 1 to 5 parts by volume of a polyethylene glycol, and iii) 4 to 10 parts by volume of water, and it does not contain any preserving agents, stabilizers, surfactants, buffers, agent for capturing free radicals, or antioxidants. 3. The pharmaceutical composition according to claim 1 or 2, comprising 1.5 to 3 parts by volume of ethanol for each part by weight of paracetamol. 4. The pharmaceutical composition according to claim 3, comprising 2 to 2.5 parts by volume of ethanol for each part by weight of paracetamol. 5. The pharmaceutical composition according to claim 1 or 2, comprising 1.0 to 4 parts by volume of polyethylene glycol for each part by weight of paracetamol. 6. The pharmaceutical composition according to claim 5, comprising 2 to 3 parts by volume of polyethylene glycol for each part by weight of paracetamol. 7. The pharmaceutical composition according to claim 1 or 2, comprising 5 to 8 parts by volume of water for each part by weight of paracetamol. 8. The pharmaceutical composition according to claim 1 or 2, wherein the polyethylene glycol is selected from the group consisting of PEG-200, PEG-300, PEG-400, PEG-1,000, PEG-1,540, PEG-4,000 and PEG-8,000. 9. The pharmaceutical composition according to claim 8, wherein the polyethylene glycol is PEG-400. 10. A clear pharmaceutical solution for injection, comprising ethanol, PEG-400, water and from 10 to 25% (w/v) of paracetamol, wherein the amounts of ethanol, of PEG-400 and of water are adjusted such that the viscosity of the said solution is between 4 and 7 mPas.
The daily respiratory system examination of COVID-19 patients who are hospitalized in the intensive care unit is performed and the necessary mechanical ventilation applications are performed by evaluating the arterial blood gas analysis. However, the lung of the patient will be evaluated by ultrasound and the position to use the lung capacity most appropriately will be given.
This project seeks to develop and validate a novel approach to training everyday memory functioning in older adults. The approach (1) trains people to use simple but effective memory skills that have broad applicability in everyday life and (2) shapes a set of skills and habits of mind that will increase the likelihood of effective use of skills and memory aids. It is based on a metacognitive perspective on self-regulation in cognitively demanding situations and informed by recent theories about how suboptimal habit patterns can be altered. The approach has not yet been used in an everyday memory intervention in high-functioning, community-dwelling older adults. The proposed research validates ecological momentary assessment methods to get actual behavioral measures of forgetting in everyday life. It then uses these procedures in a randomized experiment that contrasts the everyday memory intervention group with a traditional memory-strategy training group. The hypothesis is that the everyday memory training intervention will reduce everyday memory errors and memory complaints, whereas the memory strategy training will alter strategy use and memory performance, with little cross-over effect. The hypothesized pattern will establish the explicit benefits of our everyday memory intervention procedures and demonstrate the limitation of standard memory training for that purpose.
Participants will be provided instruction in the appropriate use of the meal replacement product. The participants will be directed to refrain from all items of food for a period of 21 days except for the meal replacement products and vitamin supplements provided by the investigators (1120 kcal/day). Optifast™ 800 total meal replacement shakes will be provided to the participants for the 21 day intervention period.
1,201,423. Iron salt-antibiotic compositions. DIAMOND SHAMROCK CORP. 5 Aug., 1968, No. 37329/68. Heading A5B. A stable, compatible, water soluble composition for adding to animal's drinking water comprises (A) ferric ammonium citrate and at least one antibiotic selected from neomycin sulphate, streptomycin sulphate, a potassium penicillin and tylosin tartrate or (B) ferric pyrophosphate and a potassium penicillin or tylosin phosphate with the proviso that the composition is free from solubilising and stabilising agents; the weight ratio of iron salt to antibiotic being 1:5 to 20:1. Solutions of the composition in water in a weight ratio of 1:80 to 1:2000 are also claimed. Other additives, e.g. vitamins may also be present.
The study will start with a dose-confirmation phase to establish safety of BPM31510 in combination with RT and TMZ. This phase will follow a standard 3+3 dose design with the starting dose of BPM31510 at 110 mg/kg/week (wk), with 1 potential dose de-escalation to 66 mg/kg/wk in the event a DLT is experienced at the 110 mg/kg dose. Toxicity at this dose level will be graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5 (CTCAE v5). Subjects will be monitored for DLTs associated with combination therapy for 30 days (d) (± 5 d) after the end of RT (DLT assessment period). Subjects will continue to be monitored for late radiation-related DLTs during follow up, every 8 wk (± 2 wk) during the first 12 months (mo), and then every 12 wk (± 2 wk) for a total of 5 years (y). Safety oversight will be provided by the independent Data and Safety Monitoring Committee (DSMC). The DSMC will review and confirm all DLT data, make recommendations for dose modifications, if necessary, and continue to monitor safety throughout the study. The efficacy phase of the study will begin after the recommended Phase 2 dose (RP2D) has been confirmed.
1,146,848. Substituted bicyclo-[2,2,2]-octanes. E. I. DU PONT DE NEMOURS & CO. 1 June, 1966 [2 June, 1965; 28 June, 1965], No. 24463/66. Heading C2C. The invention comprises (1) compounds of the formulµ (wherein R and R 1  are H, C 1-4  alkyl or allyl; and Y is H, CH 3 , C 2 H 5 , Cl, Br, F, CF 3 , OH, OCH 3  or OC 2 H 5 ) and acid-addition salts thereof; and (2) a process for preparing a 4- pyridyl or substituted pyridyl-bicyclo-(2,2,2)- octane-1-amine in which a 4-pyridyl-bicyclo- (2,2,2)-oct-2-ene-1-carboxylic acid or ester thereof is reduced by shaking in an atmosphere of hydrogen using a platinum catalyst, the ester, if used, is hydrolysed to the corresponding octane carboxylic acid, and this is then converted to the required amine by reaction with sodium azide in concentrated sulphuric acid and chloroform; or the amine is prepared by reaction of the ester with hydrazine hydrate, then with sodium nitrite in dilute acetic acid and finally heating under hydrolytic conditions, or by reaction with hydroxylamine and similar heating. The pyridine N-oxides are prepared at the ester stage by reaction with a peracid or peroxide, then conversion to the amine as described above. The amines may also be prepared by conversion of the esters to the amides and treatment of these with sodium hypohalites. The amines may be N-alkylated by standard procedures. The compounds of the invention may also be prepared by the synthetic methods indicated below. The compounds of the invention, which are stated to be anti-depressants, may be made up into pharmaceutical compositions with suitable carriers. Hard gelatine capsules, tablets and injection solutions containing 4-(4-pyridyl)- bicyclo-[2,2,2] -octane- 1-amine dihydrochloride and soft gelatine capsules containing the corresponding free base are described.
This prospective randomized controlled study was approved by IRB of our institute.

Patients requiring nasotracheal intubation will be screened for eligibility of the study. Then, patients will be randomized to one of two groups; (group I: tube advancement in neutral / group II: tube advancement with the tube counter-clockwise rotated). After induction of anesthesia and muscle relaxation, the preformed nasal RAE (Ring-Adair-Elwyn) tube will be inserted via a nostril approximately 3-4 cm. Next, an anesthesiologist will advance the tube, with it neutral, continuously into the oral cavity of the patients in Group I, while the anesthesiologist will advance the tube, with it rotated counter-clockwise in 90 degree, into the oral cavity of the patients in Group II. After the tube will be placed in the oral cavity, the anesthesiologist will perform nasotracheal intubation with Magill forceps. After that, an investigator will check occurrence of epistaxis due to nasotracheal intubation and its severity with a fiberoptic bronchoscope. After obtainment of all data, investigators will analyze incidence of epistaxis and its severity between two groups.
BACKGROUND: Sepsis is triggered by pathogenic microorganisms, resulting in a systemic inflammatory response. Liver cirrhosis and sepsis create a vicious cycle: cirrhosis weakens immune function, raising infection risk and hindering pathogen clearance. Optimal treatment outcomes depend on understanding liver cirrhosis patients' sepsis risk factors. Thus, preventing sepsis involves addressing these risk factors. Therefore, early identification and understanding of clinical characteristics in liver cirrhosis patients with sepsis are crucial for selecting appropriate antibiotics. A case-control study using logistic regression was conducted to examine the prognostic value of amyloid A/lactate level monitoring in identifying sepsis risk factors in liver cirrhosis patients.
METHODS: From March 2020 to March 2022, 136 liver cirrhosis patients treated at our hospital were divided into a sepsis group (n = 35) and a non-sepsis group (n = 101) based on sepsis complications. General clinical data were collected. Univariate analysis screened for liver cirrhosis patients' sepsis risk factors. Multivariate logistic analysis was subsequently employed to evaluate the risk factors. Sepsis patients were followed up for a month. Based on prognosis, patients were categorized into a poor prognosis group (n = 16) and a good prognosis group (n = 19). Serum amyloid A (SAA) and blood lactic acid (BLA) levels were compared between the two groups. The receiver operating characteristic (ROC) curve was used to evaluate the prognostic value of both individual and combined SAA/BLA monitoring.
RESULTS: Patient data, including age, diabetes history, liver cancer, hepatic artery embolization, recent antibiotic use, invasive procedures within two weeks, APACHE II Scoring, ALB and SAA and BLA levels, were compared between the sepsis and non-sepsis groups, showing significant differences (P < 0.05). Logistic regression identified factors such as age ≥ 70, recent antibiotic use, recent invasive procedures, history of liver cancer, hepatic artery embolization history, high APACHE II scores, decreased albumin, and elevated SAA and BLA levels as independent sepsis risk factors in liver cirrhosis patients (P < 0.05). Among the 35 sepsis patients, 16 had a poor prognosis, representing an incidence rate of 45.71%. Serum SAA and BLA levels were significantly higher in the poor prognosis group than in the good prognosis group (P < 0.05). The AUC for serum SAA and BLA was 0.831 (95%CI: 0.738-0.924), 0.720 (95%CI: 0.600-0.840), and 0.909 (95%CI: 0.847-0.972), respectively. The combined diagnostic AUC was significantly higher than that of single factor predictions (P < 0.05). The predictive value ranked as follows: joint detection > SAA > BLA.
CONCLUSION: In treating liver cirrhosis, prioritize patients with advanced age, a history of hepatic artery embolization, recent invasive operations, history of liver cancer, recent antibiotic exposure, high APACHE II scores and low albumin. Closely monitoring serum SAA and BLA levels in these patients can offer valuable insights for early clinical prevention and treatment.
The present invention relates to a pharmaceutical composition for treating thyroid cancer including a combination of evodiamine with histone deacetylase inhibitor having an effect upon the survival of thyroid cancer cells. Human thyroid cancer cells, TPC-1 and SW1736, are used. When treating the thyroid cancer cells with a combination of evodiamine with PXD101, cell survival rate, survived cell ratio and Bcl2 protein level are reduced, and the cytotoxic activity, ratio of apoptosis cells and γH2AX, acetyl histone H3 and cleaved PARP protein level and production of active oxygen species are increased. In the cells treated with evodiamine in combination with PXD101, cell survival rate is reduced, survived cell ratio and Bcl2 protein levels are reduced, cytotoxic activity is increased, and an increase in destroyed cells is induced, as compared to the cells treated with PXD101 alone. In addition, γH2AX protein level, cleaved PARP and production of active oxygen species are increased, and Bcl2/Bax ratio is reduced. Further, the combined index value of evodiamine with PXD101 is lower than 1.0. As a result, it is shown that evodiamine controls survival-related proteins and active oxygen species in thyroid cancer cells, and thus shows a synergic effect with histone deacetylase inhibitor causing cytotoxicity. In addition, inhibition of PI3K/Akt signals synergistically reinforces the cytotoxicity of evodiamine combined with histone deacetylase inhibitor in thyroid cancer cells.
The trusted messenger patient intervention will involve training a small number of staff "trusted messengers" to engage patients informally and assist with building vaccine confidence in brief one- on-one sessions, supported by trusted messengers weekly consultations with a content expert who can answer specific vaccine related questions that patients have over a 3-week period. Trusted messengers will be full time unit employees, selected with the assistance of the nursing supervisor for having excellent rapport with patients (assessed with the Nurse Coordinator Questionnaire) and for having been vaccinated. Mental health workers or nurses may serve in this role. Both inpatient units involved in this study will be grouped into the same vaccination cohort within the hospital, to provide patients in the intervention and the wait list similar opportunities to be vaccinated.
Long-term carcinogenicity studies have been performed in Sprague Dawley rats at doses of 150, 300, and 450 mg/kg/day in males and 150, 450, 900, and 1,200 mg/kg/day in females. These doses are approximately 2, 4, and 8 times in males, and 3, 7, 12, and 16 times in females of the maximum recommended human daily dose of 2,000 mg based on body surface area comparisons. No evidence of carcinogenicity with metformin was found in either male or female rats. A carcinogenicity study was also performed in Tg.AC transgenic mice at doses up to 2,000 mg applied dermally. No evidence of carcinogenicity was observed in male or female mice.

  


Genotoxicity assessments in the Ames test, gene mutation test (mouse lymphoma cells), chromosomal aberrations test (human lymphocytes) and in vivo mouse micronucleus tests were negative. Fertility of male or female rats was not affected by metformin when administered at doses up to 600 mg/kg/day, which is approximately 3 times the maximum recommended human daily dose based on body surface area comparisons.
The present invention discloses a Chinese materia medica preparation for curing cholecystitis and a preparation method thereof. The Chinese materia medica preparation is mainly prepared from bupleurum root, curcuma root, toosendan fruit, aucklandia root, corydalis tuber, aurantii, radix gentianae, rhubarb, pinellia tuber, nutagrass flatsedge rhizome, lysimachia, endothelium corneum gigeriae galli, amomun fruit, forsythia fruit, giant knotweed rhizome and honeysuckle flower. The raw materials are selected elaborately, washed and dried according to the proportion by weight; the sixteen kinds of traditional Chinese medicine are mixed and crushed into fine powder of 180 meshes by a pulverizer; every package contains 5 to 8g of fine powder by measurement; auxiliary materials can be added to the powder to make tablets by the tablet making technology, or auxiliary materials are added to the powder to make water-paste pills by the water-paste pill making technology, or auxiliary materials are added to the powder to make honeyed pills by the honeyed pill making technology; the medicinal powder is filled in capsules to make capsules. The clinical treatment of several years proves that the cure rate can reach 98% and effective rate can reach 99.7%. The Chinese materia medica preparation has the advantage of medicine taking convenience, without boiling, and is suitable for making various preparations in factories of traditional Chinese medicine. The Chinese materia medica preparation has maximum characteristics that the Chinese materia medica preparation has no toxic side effect, and does not cause the uncomfortable feelings of the stomach, spleen and lung; thus, patients can cure cholecystitis with easy and happy feelings.
BACKGROUND: Myocardial ischemia/reperfusion (I/R) injury stands as a primary contributor to ischemic heart disease. Sevoflurane (SEVO), a commonly used inhalation anesthetic, has been shown to exert a direct protective effect on ischemic heart injury. However, the specific mechanism by which it exerts the protective effect remains unclear. This study was designed to investigate the role of SEVO in myocardial I/R injury and its potential molecular mechanisms.
METHODS: Blood samples were collected from patients with acute myocardial infarction (AMI) (n = 20) and healthy volunteers (n = 20). The human cardiomyocytes AC16 models of I/R injury were induced by hypoxia/reoxygenation. The mRNA expression levels of growth differentiation factor 11 (GDF11) in the cells and blood were determined by reverse transcription quantitative real-time PCR (RT-qPCR). The cell proliferation was detected by Cell Counting Kit-8 (CCK-8). Enzyme-Linked Immunosorbent Assay (ELISA) was utilized to detect the levels of inflammatory factors interleukin (IL)-8, IL-1β and IL-6 in the cells. And biochemical assay kits were applied for the measurement of the activity of lactate dehydrogenase (LDH) and superoxide dismutase (SOD) as well as the malondialdehyde (MDA) level in the cells. Moreover, western blot was employed to evaluate the levels of the p-serine-threonine protein kinase (AKT), AKT, and phosphatidylinositol 3-kinase (PI3K), protein expression in the cells.
RESULTS: The GDF11 expression was decreased in the blood of AMI patients and cardiomyocytes induced by I/R (p < 0.01). Besides, 1% SEVO was presented to promote cardiomyocyte proliferation, inhibit apoptosis, oxidative stress and inflammation, and activate the PI3K/AKT signaling pathway through up-regulation of GDF11 expression (p < 0.01).
CONCLUSION: SEVO promotes proliferation and inhibits inflammatory response, apoptosis, and oxidative stress of I/R-treated cardiomyocytes by elevating GDF11 expression, thereby reducing myocardial I/R injury. Notably, the mechanism underlying the alleviation of the I/R injury may involve the activation of PI3K/AKT signaling pathway.
Background: Myocardial infarction (MI) is a common cardiovascular disease with a high fatality rate once accompanied by cardiogenic shock. The efficacy of extracorporeal membrane oxygenation (ECMO) in treating MI is controversial. Methods: MI was induced by ligating the left anterior descending artery (LAD) in adult male rats. Groups were defined as follows: MI group, reperfusion for 90 min after 30 min of LAD occlusion; MI + ECMO group, reperfusion and ECMO were performed for 90 min immediately after 30 min of LAD occlusion; prolonged MI + ECMO group, ECMO was used immediately after 30 min of occlusion with persistent occlusion of the LAD for an additional 30 min, followed by 90 min of reperfusion. The myocardial infarct size and mitochondrial morphology and function data were collected and compared of each group. Results: The ECMO groups had a smaller myocardial infarct size and larger percentage ejection fraction. Compared with the prolonged MI + ECMO group, the immediate reperfusion group had a lower percentage of infarct size (63.28% vs. 17.97% vs. 31.22%, MI vs. MI + ECMO vs. prolonged MI + ECMO). Mitochondria isolated from the ischemic zone showed an intact mitochondrial structure, including fewer voids and broken cristae, and preserved activity of mitochondrial complex II and complex IV in ECMO groups. Conclusions: ECMO support in MI can reduce myocardial injury despite delayed coronary reperfusion.
OBJECTIVE: To evaluate the association between hospital volume and the quality of gynecologic emergency care for tubal ectopic pregnancies, ovarian torsion, and pelvic inflammatory disease (PID).
METHODS: In this cross-sectional analysis, we analyzed patients who presented for emergency care for tubal ectopic pregnancies, ovarian torsion, and PID using the Premier Healthcare Database from 2006 to 2020. We measured the following outcomes: methotrexate use for ectopic pregnancy, ovarian cystectomy for torsion, and guideline-based antibiotic use for PID. For each condition, we measured outlier hospitals that performed the above interventions at below the 10th percentile. Multivariable logistic regression models were used to analyze associations between outlier care and hospital factors such as annualized mean case volume, urban or rural location, teaching status, bed capacity, and geographic region, as well as hospital-level patient population factors, including age, insurance status, and race.
RESULTS: A total of 602 hospitals treated patients with tubal ectopic pregnancies, of which 21.9% were outliers, with no cases managed with methotrexate. Of 512 hospitals treating patients with ovarian torsion, 17.4% were outliers, with no cases managed with cystectomy. Of 929 hospitals that treated patients with PID, 9.9% were deemed outliers with low rates of guideline-adherent antibiotic administration. Low-volume hospitals were more likely to be outliers with low rates of use of methotrexate for ectopic pregnancy (6.7% of high-volume hospitals vs 49.7% of low-volume hospitals were outliers; adjusted odds ratio [aOR] 0.13, 95% CI, 0.05-0.31 for high-volume hospitals) and cystectomy for torsion (34.9% of low-volume vs 2.4% of high-volume hospitals were outliers; aOR 0.05, 95% CI, 0.01-0.18 for high-volume hospitals). There was no association between hospital volume and lower rates of guideline-based antibiotic use for PID.
CONCLUSION: Higher hospital volume is associated with use of conservative, fertility-preserving treatment of emergency gynecologic conditions, including ectopic pregnancy and ovarian torsion.